{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:55:02Z","timestamp":1784076902026,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","award":["BPN\/WAL\/2023\/1\/00061"],"award-info":[{"award-number":["BPN\/WAL\/2023\/1\/00061"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","award":["S2023-0006"],"award-info":[{"award-number":["S2023-0006"]}],"id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T17:29:07Z","timestamp":1745688547000},"page":"1673-1684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"given":"Akihiro","family":"Matsukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi Kardoust","family":"Parizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Litterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Benedetto","family":"Galosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.02.009_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bju.14872","article-title":"The natural history of untreated muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.009_b0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2013.09.050","article-title":"Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.juro.2009.02.120","article-title":"A population based assessment of perioperative mortality after cystectomy for bladder cancer","volume":"182","author":"Isbarn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0020","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2025.02.009_b0025","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1158\/1078-0432.CCR-10-0457","article-title":"The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder","volume":"16","author":"Svatek","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.02.009_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104321","article-title":"Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: a systematic review and network meta-analysis","volume":"196","author":"Monteiro","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2025.02.009_b0035","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.009_b0040","article-title":"Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer","volume":"5","author":"Galsky","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euo.2025.02.009_b0045","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s11864-023-01113-z","article-title":"Perioperative immunotherapy in muscle-invasive bladder cancer","volume":"24","author":"Singh","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103570","article-title":"Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes","volume":"169","author":"Laukhtina","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2025.02.009_b0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/iju.15319","article-title":"Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: a systematic review and network meta-analysis","volume":"31","author":"Mori","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.009_b0065","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.009_b0070","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.009_b0075","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1186\/s12885-021-08990-3","article-title":"Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004-AURA trial)","volume":"21","author":"Martinez Chanza","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2025.02.009_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.euo.2025.02.009_b0085","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.02.009_b0090","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2024"},{"key":"10.1016\/j.euo.2025.02.009_b0095","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.02.009_b0100","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2025.02.009_b0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","article-title":"Meta-analysis of proportions using generalized linear mixed models","volume":"31","author":"Lin","year":"2020","journal-title":"Epidemiology"},{"key":"10.1016\/j.euo.2025.02.009_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99078-2","article-title":"An efficient and accurate distributed learning algorithm for modeling multi-site zero-inflated count outcomes","volume":"11","author":"Edmondson","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2025.02.009_b0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.euo.2025.02.009_b0120","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.euo.2025.02.009_b0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euo.2025.02.009_b0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2023.06.014","article-title":"Long-term outcomes from a phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695)","volume":"84","author":"Flaig","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0140","doi-asserted-by":"crossref","first-page":"eS8","DOI":"10.1016\/S0007-4551(20)30281-2","article-title":"Open-label phase II to evaluate the efficacy of neoadjuvant dose-dense MVAC in combination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO","volume":"107","author":"Thibault","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.euo.2025.02.009_b0145","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1470-2045(22)00158-9","article-title":"Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial","volume":"23","author":"Hussain","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.02.009_b0150","volume":"40","author":"Grivas","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2025.02.009_b0155","first-page":"5102","article-title":"DUTRENEO trial: a randomized phase II trial of durvalumab and tremelimumab versus chemotherapy as a neoadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0160","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/jjco\/hyaa123","article-title":"Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study","volume":"50","author":"Kitamura","year":"2020","journal-title":"Jpn J Clin Onco"},{"key":"10.1016\/j.euo.2025.02.009_b0165","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.009_b0175","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0022-5347(01)67614-6","article-title":"Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study","volume":"153","author":"Martinez-Pi\u00f1eiro","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0180","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2025.02.009_b0185","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1200\/JCO.2024.42.16_suppl.4593","article-title":"Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: the NABUCCO trial update","volume":"42","author":"Stockem","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0190","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.euo.2023.11.022","article-title":"PrECOG PrE0807: a phase 1b feasibility trial of neoadjuvant nivolumab without and with lirilumab in patients with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based neoadjuvant chemotherapy","volume":"7","author":"Grivas","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2025.02.009_b0195","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2022.40.16_suppl.4515","article-title":"Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): primary analysis of the single arm phase II trial SAKK 06\/17","volume":"40","author":"Cathomas","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0200","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1002\/cam4.5900","article-title":"Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: a multi-center, single-arm, phase 2 study","volume":"12","author":"Han","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2025.02.009_b0205","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4143\/crt.2022.343","article-title":"Neoadjuvant nivolumab plus gemcitabine\/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.euo.2025.02.009_b0210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ajco.13996","article-title":"Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder","volume":"19","author":"Park","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.02.009_b0215","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","article-title":"HCRN GU14-188: phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer","volume":"41","author":"Brown","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2025.02.009_b0220","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1200\/JCO.2022.40.16_suppl.4580","article-title":"Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC","volume":"40","author":"Lin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.02.009_b0225","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2022.40.6_suppl.535","article-title":"Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma","volume":"40","author":"Goubet","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0230","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.02.009_b0235","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.02.009_b0240","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2022.40.6_suppl.498","article-title":"Neoadjuvant nivolumab (N) +\/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)","volume":"40","author":"Guercio","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0245","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.euo.2020.11.010","article-title":"Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from the ABACUS trial","volume":"4","author":"Szabados","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.02.009_b0250","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2021.39.6_suppl.442","article-title":"Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy","volume":"39","author":"Koshkin","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0255","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.02.009_b0260","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.02.009_b0265","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2020.38.6_suppl.507","article-title":"Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2","volume":"38","author":"Wei","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0270","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.02.009_b0275","unstructured":"Garcia JA, Case Comprehensive Cancer Center. Phase II single arm, open label, single institution study of neoadjuvant sunitinib (SUTENT) in patients with muscle-invasive locally advanced transitional cell carcinoma of the bladder. https:\/\/clinicaltrials.gov\/study\/NCT00526656."},{"key":"10.1016\/j.euo.2025.02.009_b0280","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","article-title":"Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer","volume":"36","author":"Iyer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0285","first-page":"6453","article-title":"Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: a prospective clinical trial based on cisplatin feasibility","volume":"37","author":"Schinzari","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.euo.2025.02.009_b0290","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000463389","article-title":"neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer","volume":"93","author":"Nieders\u00fcss-Beke","year":"2017","journal-title":"Oncology."},{"key":"10.1016\/j.euo.2025.02.009_b0295","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4143\/crt.2015.405","article-title":"Cisplatin, gemcitabine, and lapatinib as neoadjuvant therapy for muscle-invasive bladder cancer","volume":"48","author":"Narayan","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.euo.2025.02.009_b0300","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0305","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s10147-012-0447-z","article-title":"Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study","volume":"18","author":"Koie","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.urology.2013.03.044","article-title":"A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder","volume":"82","author":"Grivas","year":"2013","journal-title":"Urology"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2025.02.009_b0315","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/jco.2012.30.15_suppl.4581","article-title":"Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC)","volume":"30","author":"Balar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0320","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1590\/S1677-55382007000500004","article-title":"Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma","volume":"33","author":"Herchenhorn","year":"2007","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0325","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-5347(01)66230-X","article-title":"Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma","volume":"155","author":"Logothetis","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000065713","article-title":"Neoadjuvant chemotherapy with sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin for locally advanced bladder cancer","volume":"63","author":"Nishiyama","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.euo.2025.02.009_b0335","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000475030","article-title":"Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer","volume":"28","author":"Scattoni","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0340","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0022-5347(17)42495-5","article-title":"Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion","volume":"139","author":"Scher","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0345","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1442-2042.2002.00443.x","article-title":"Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial","volume":"9","author":"Sousa-Escandon","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0350","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(17)37031-3","article-title":"A European Organization for Research and Treatment of Cancer\u2013Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response","volume":"148","author":"Splinter","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0355","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0360","doi-asserted-by":"crossref","first-page":"732.e9","DOI":"10.1016\/j.urolonc.2021.03.004","article-title":"Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer","volume":"39","author":"Khaki","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0365","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.02.009_b0370","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.02.009_b0375","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskim\u00e4e","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0380","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of divergent differentiation and\/or histological subtype of urothelial carcinoma on patient outcomes in the GETUG-AFU V05 VESPER trial","volume":"211","author":"Allory","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.009_b0385","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"Suppl 5","key":"10.1016\/j.euo.2025.02.009_b0390","article-title":"988TiP \u2013 KEYNOTE-866: phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)","volume":"30","author":"Siefker-Radtke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0395","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0400","first-page":"205","article-title":"Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder","volume":"10","author":"Sanguedolce","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.009_b0405","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.euo.2025.02.009_b0410","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.4103\/jcrt.jcrt_1297_22","article-title":"Prognostic importance of PD-L1 expression in bladder cancer patients","volume":"19","author":"Durur","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.euo.2025.02.009_b0415","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:41:48Z","timestamp":1778143308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125000434"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}